Merck (MRK) Tops Analyst Estimates on Strong Keytruda, Gardasil, and Bridion Sales
Tweet Send to a Friend
Merck's (NYSE: MRK) shares dipped in the early part of Thursday's session after it reported second-quarter earnings. Profit and revenue ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


